CTT Pharma Signs LOI for Clinical Trials on Nicotine Products

CTT Pharmaceutical Holdings, Inc. has taken a significant step forward by signing a Letter of Intent (LOI) with a U.S. testing company. This agreement aims to conduct clinical trials for various nicotine products utilizing CTT's patented technology. This partnership could enable CTT to independently enter the U.S. market with its innovative solutions. As developments occur, the company plans to keep its shareholders informed.

CTT Pharma specializes in thin film oral drug delivery systems, offering rapid onset and enhanced efficiency. The focus is on providing an alternative to traditional dosage forms across multiple markets. With an emphasis on scientific validation and regulatory readiness, CTT aims to support its product innovation and growth strategy.